Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy
Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).
1 finding from 1 review
1Small sample size. · people with nerve damage (< 6 months' duration) in leprosy
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Improvement in sensory nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
Corticosteroids showed no clear difference in improvement in sensory nerve function at 1 year compared with placebo (moderate certainty).
1 finding from 1 review
Improvement in motor nerve function at 1 year · people with nerve damage (6 to 24 months' duration) in leprosy
1 finding from 1 review
Incomplete recovery at end of study № of participants: 766 (3 RCTs) · Bell's palsy
Antivirals plus corticosteroids showed no clear difference in incomplete recovery at end of study № of participants: 766 (3 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (low certainty).
1 finding from 1 review
RR 0.81 [0.38, 1.74]
Studies not reported
Low
Motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) · Bell's palsy
Antivirals plus corticosteroids probably leads to lower motor synkinesis or crocodile tears № of participants: 469 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (moderate certainty).
1 finding from 1 review
RR 0.56 [0.36, 0.87]
Studies not reported
Moderate
Adverse events № of participants: 656 (2 RCTs) · Bell's palsy
It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).
1 finding from 1 review
RR 1.17 [0.81, 1.68]
Studies not reported
Very low
Change in sensory score after one year · patients with nerve damage in leprosy
1 finding from 1 review
Proportion of ulnar nerves with sensory improvement after one year · patients with nerve damage in leprosy
It is very uncertain whether medial epicondylectomy plus oral steroids changes proportion of ulnar nerves with sensory improvement after one year compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in motor score after one year · patients with nerve damage in leprosy
1 finding from 1 review
Proportion of ulnar nerves with motor improvement after one year · patients with nerve damage in leprosy
It is very uncertain whether medial epicondylectomy plus oral steroids changes proportion of ulnar nerves with motor improvement after one year compared with oral steroids alone (very low certainty).
1 finding from 1 review
Change in sensory score after two years · patients with nerve damage in leprosy
1 finding from 1 review
Change in motor score after two years · patients with nerve damage in leprosy
1 finding from 1 review
Death ‐ at 180 days after ICU admission, in total population randomised · critically ill patients
Corticosteroids showed no clear difference in death ‐ death at 180 days in total population randomised compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ shock · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ shock compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ serious infection · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ serious infection compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients
Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).
1 finding from 1 review
Serious adverse events (continuous data) ‐ blood glucose (mg/dL) on day 7 · critically ill patients
1 finding from 1 review
Occurrence of CIP/CIM ‐ in the total population randomised · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in total population randomised compared with placebo compared (low certainty).
1 finding from 1 review
Occurrence of CIP/CIM ‐ in screened population · critically ill patients
Corticosteroids showed no clear difference in occurrence of CIP/CIM ‐ in screened population compared with placebo compared (moderate certainty).
1 finding from 1 review